Fig. 3: rLASV/IGR-CD is attenuated in vivo.
From: A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs
A Study design, B Kaplan–Meier survival curve, and C–E clinical observations of strain 13 guinea pigs exposed to 105 PFU of rLASV-WT (n = 8) or rLASV/IGR-CD (n = 8). “Mild signs” indicates ruffled fur, increased respiration rate, and slightly reduced activity. “Moderate signs” indicates ruffled fur, partially closed eyes, increased respiration rate with abdominal activity, and significantly reduced activity. “Severe signs” indicates respiratory distress, closed or mostly closed eyes, severe lethargy, and cyanosis. Error bars indicate standard error of the mean. **p < 0.005, ***p < 0.0005, ****p < 0.0001. CD codon-deoptimized; EDTA ethylenediaminetetraacetic acid; IGR intergenic region; LASV Lassa virus; rLASV recombinant LASV; PFU plaque-forming units; WT wild-type.
